These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 17124283)

  • 1. Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD).
    Fujii N; Hamano T; Mikami S; Nagasawa Y; Isaka Y; Moriyama T; Horio M; Imai E; Hori M; Ito T
    Nephrol Dial Transplant; 2007 Jun; 22(6):1601-7. PubMed ID: 17124283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease.
    Kikuchi Y; Imakiire T; Yamada M; Saigusa T; Hyodo T; Kushiyama T; Higashi K; Hyodo N; Yamamoto K; Suzuki S; Miura S
    Nephrol Dial Transplant; 2007 Jun; 22(6):1593-600. PubMed ID: 17041001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.
    Morishita M; Nagashima M; Wauke K; Takahashi H; Takenouchi K
    J Rheumatol; 2008 Mar; 35(3):407-13. PubMed ID: 18260178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.
    Izumi K; Mizokami A; Sugimoto K; Narimoto K; Miwa S; Maeda Y; Kadono Y; Takashima M; Koh E; Namiki M
    Urology; 2009 Jun; 73(6):1342-6. PubMed ID: 19371939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
    Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
    Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
    Bahlous A; Bouzid K; Sahli H; Sallami S; Abdelmoula J
    Tunis Med; 2009 Jun; 87(6):380-1. PubMed ID: 19927782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
    Hooper MJ; Ebeling PR; Roberts AP; Graham JJ; Nicholson GC; D'Emden M; Ernst TF; Wenderoth D
    Climacteric; 2005 Sep; 8(3):251-62. PubMed ID: 16390757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
    Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
    Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease.
    Hamano T; Fujii N; Nagasawa Y; Isaka Y; Moriyama T; Okada N; Imai E; Horio M; Ito T
    Bone; 2006 Nov; 39(5):1067-1072. PubMed ID: 16781904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly risedronate in kidney transplant patients with osteopenia.
    Torregrosa JV; Fuster D; Pedroso S; Diekmann F; Campistol JM; Rubí S; Oppenheimer F
    Transpl Int; 2007 Aug; 20(8):708-11. PubMed ID: 17555530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients.
    Torregrosa JV; Fuster D; Gentil MA; Marcen R; Guirado L; Zarraga S; Bravo J; Burgos D; Monegal A; Muxí A; García S
    Transplantation; 2010 Jun; 89(12):1476-81. PubMed ID: 20393402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of vitamin K(2) and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats.
    Iwamoto J; Matsumoto H; Takeda T; Sato Y; Liu X; Yeh JK
    Calcif Tissue Int; 2008 Aug; 83(2):121-8. PubMed ID: 18543014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
    AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of short-term risedronate on bone resorption and patient satisfaction in postmenopausal osteoporosis patients.
    Fernandes CE; Zerbini C; Russo LA; Albernaz MA; Eis SR; Szejnfeld VL; Pompei LM
    J Clin Densitom; 2009; 12(1):77-83. PubMed ID: 19004654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
    Dane C; Dane B; Cetin A; Erginbas M
    Gynecol Endocrinol; 2008 Apr; 24(4):207-13. PubMed ID: 18382907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
    Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
    Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study.
    Racewicz AJ; Schofield PJ; Cahall DL; Cline GA; Burgio DE
    Curr Med Res Opin; 2007 Dec; 23(12):3079-89. PubMed ID: 17971285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
    Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
    J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
    Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.